01—Abstract
Summary
Summary of the 8-K filed November 4, 2025. Cited figures are marked; the original filing is the authoritative source.
Amgen's third-quarter 2025 results show a mixed picture: top-line strength paired with a sharp GAAP earnings hit from a $400 milliona Otezla intangible asset impairment.
Total revenues rose 12% to $9.6 billionb, driven by 14% volume growth in product sales, and sixteen products grew at double-digit rates, including Repatha (+40%), EVENITY (+36%), TEZSPIRE (+40%), and BLINCYTO (+20%). GAAP EPS rose 14% to $5.93 from $5.22, but non-GAAP EPS grew only 1% to $5.64 as non-GAAP operating margin fell 2.5 points to 47.1%, reflecting a 31% increase in R&D spend tied to late-stage programs such as MariTide, where six global Phase 3 studies are underway. Enbrel sales fell 30% on Medicare Part D redesign and U.S. net price pressure, a headwind that is likely to persist.
Cash generation was the quarter's clear bright spot. Free cash flow reached $4.2 billionc versus $3.3 billion a year earlier, helped by working capital timing and lower interest payments. Amgen retired $1.6 billion of debt in the quarter and $6.0 billion year to date, reducing total debt to $54.6 billion from $60.1 billion at year-end 2024.
No shares were repurchased in Q3, and the company paid a $2.38d quarterly dividend, up 6% year over year. Management kept full-year 2025 guidance essentially intact, with revenue of $35.8–36.6 billion and non-GAAP EPS of $20.60–21.40, though the GAAP range was not changed to reflect future impairments or equity gains. Pipeline news was the other key focus.
Repatha's Phase 3 VESALIUS-CV trial met its dual primary endpoints in patients without prior heart attack or stroke, a potentially significant label expansion to be presented at AHA on November 8. Upcoming catalysts include FDA decisions on UPLIZNA for generalized myasthenia gravis (PDUFA December 14, 2025) and IMDELLTRA for relapsed ES-SCLC (PDUFA December 18, 2025), along with MariTide Phase 2 data in Q4 2025. Investors should weigh strong volume momentum and the late-stage pipeline against margin compression, Enbrel erosion, and the continuing risk of further intangible asset impairments.
02—Key points
Key Highlights
- Total revenues rose 12% to $9.6 billion in Q3 2025, with product sales up 12% on 14% volume growth, partly offset by 4% lower net selling prices.
- GAAP EPS rose 14% to $5.93, but non-GAAP EPS grew only 1% to $5.64, as non-GAAP operating margin fell 2.5 points to 47.1% on higher R&D (+31%) and SG&A (+9%) spending.
- A $400 million Otezla intangible asset impairment in Q3 depressed GAAP operating margin and is excluded from non-GAAP results; FY2025 impairments now total $1.2 billion year to date.
- Free cash flow reached $4.2 billion versus $3.3 billion in Q3 2024, aided by working capital timing and lower interest payments.
- Debt fell to $54.6 billion from $60.1 billion at year-end 2024 after $6.0 billion of debt retirement year to date; no share repurchases were made in Q3.
- Enbrel sales declined 30% to $580 million on U.S. Medicare Part D redesign and 38% lower net selling price, while Repatha (+40%), EVENITY (+36%), and TEZSPIRE (+40%) led growth.
- Repatha's Phase 3 VESALIUS-CV trial met its dual primary endpoints, with full results due at AHA on November 8, 2025; FY2025 guidance was maintained at revenue of $35.8–36.6 billion and non-GAAP EPS of $20.60–21.40.
03—Questions
Frequently Asked Questions
Why did GAAP EPS rise while non-GAAP EPS barely grew?
GAAP EPS benefited from $1.96 billion of net gains on equity investments, primarily the BeOne Medicines stake, which are excluded from non-GAAP results. Non-GAAP EPS rose only 1% because non-GAAP operating income growth was offset by a higher effective non-GAAP tax rate (18.2% versus 13.4%) and a lower non-GAAP other income line. Investors should therefore focus on the non-GAAP figures for underlying operating performance.
How significant is the $400 million Otezla impairment?
It is a non-cash charge tied to Otezla's intangible assets acquired in business combinations, and it is excluded from non-GAAP results. It reduced Q3 GAAP operating income and pushed GAAP operating expenses up sharply. Year-to-date impairments total $1.2 billion, and the guidance bridge shows an impairment adjustment of about $1.94 per share for 2025. Further impairments are possible if Otezla's outlook weakens, which makes this a key area to monitor.
Is Amgen's guidance changing?
Amgen maintained its full-year 2025 revenue guidance of $35.8–36.6 billion and non-GAAP EPS of $20.60–21.40. GAAP EPS guidance of $13.76–14.60 reflects the impairments and equity gains recognized so far. The company notes that guidance excludes future GAAP adjustments such as acquisitions, impairments, litigation, and equity investment fair value changes, and does not include tariffs or pricing actions not yet implemented.
What are the near-term catalysts for investors?
Key events include the AHA presentation of VESALIUS-CV on November 8, 2025, which could support a Repatha label expansion to patients without prior heart attack or stroke; Q4 2025 Phase 2 readouts for MariTide in obesity and type 2 diabetes; the FDA PDUFA date for UPLIZNA in generalized myasthenia gravis on December 14, 2025; and the PDUFA date for IMDELLTRA in relapsed ES-SCLC on December 18, 2025. Positive outcomes would support the growth narrative, while setbacks could weigh on sentiment given elevated R&D spending.
Why is operating margin declining despite strong revenue growth?
Non-GAAP operating margin fell 2.5 points to 47.1% because operating expenses grew 18%, faster than revenue. R&D rose 31% to $1.9 billion, driven by late-stage programs including MariTide, and SG&A rose 9%. Cost of sales as a share of product sales also rose 0.4 points on higher profit-share expense and sales mix. Management is investing heavily in pipeline expansion, so investors should weigh near-term margin pressure against long-term growth potential.
04—Continue